Mumbai, August 13, 2024: Supriya Lifescience Ltd., a cGMP-compliant company with a solid track record in API manufacturing and an emphasis on products from a range of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anesthetic, and anti-asthmatic, has released its financial statements for the first quarter of Q1 FY 25.
Q1 FY25 Performance Highlights:
Supriya Lifescience Ltd. saw impressive revenue growth in the first quarter of FY25, reporting a 21.7% year-over-year rise to Rs. 160.63 crore from Rs. 132.02 crore in Q1 FY24.
EBITDA for Q1 FY25 stood at Rs. 62.54 crore, with an EBITDA Margin of 38.9%, as opposed to an EBITDA of Rs. 44.49 crore in Q1 FY24 with an EBITDA margin of 33.7%. This is a 40.6% YoY increase.
In Q1 FY25, the Profit After Tax (PAT) was Rs 44.64 crore as opposed to Rs 28.51 crore in Q1 FY24.
In Q1 FY25, the PAT Margin was 27.8%, as opposed to 21.6% in Q1 FY24.
In Q1FY25, the business had strong growth in a variety of therapeutic areas.
European markets now contribute 51% of our business revenue up from 43% in Q4FY24 and 34% in Q1FY24.
Highlights of the Consolidated Financials:
“We are engaged in discussions with a diverse range of companies, from major pharmaceutical firms to innovative enterprises, to establish partnerships for supplying tailored products,” stated Dr. Saloni Wagh, Managing Director of Supriya Lifescience Ltd., in response to the results. During the previous fiscal year, the firm spent a record-breaking Rs. 146 crore on capital expenditures and increased its return on equity by 210 basis points.
We are pleased to present our brand-new research and development center in Lote Parshuram, and we plan to have our lab in Ambernath finished by early Q2FY25. Our next phase of growth will be driven by these cutting-edge facilities, which will concentrate on CMO/CDMO prospects, advanced product development, and portfolio expansion to satisfy changing market demands. The firm wants to develop significantly and become more profitable in the future.